Drug intelligence / Profile preview

estradiol valerate + progesterone (Schering AG)

Development stage
Phase 4
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral, Vaginal, Intramuscular
01

Overview

This specific hormone replacement therapy (HRT) regimen is a combination protocol used for endometrial preparation in women undergoing frozen embryo transfer (FET) as part of assisted reproductive technology (ART). The protocol, as evaluated in clinical trials by Malihe Mahmoudinia, involves the sequential administration of **estradiol valerate** and **progesterone**. Estradiol valerate is typically initiated early in the menstrual cycle to stimulate endometrial proliferation and reach an optimal thickness (≥8 mm). Once the endometrium is prepared, progesterone supplementation is introduced via vaginal suppositories and intramuscular injections to induce the secretory transformation of the endometrium, mimicking the natural luteal phase and creating a receptive environment for embryo implantation. This "artificial cycle" approach is particularly useful for patients with irregular menstrual cycles or to facilitate the scheduling of embryo transfers.

Other names
Artificial Cycle FEThormone replacement therapy (HRT) groupHRT protocol for frozen embryo transfer
02

Targets

ESR1 (ERα)ESR2 (ERβ)GPER1 (G protein-coupled estrogen receptor 1)PR (Progesterone receptor)

Beyond the preview

Go deeper on estradiol valerate + progesterone (Schering AG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on estradiol valerate + progesterone (Schering AG).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call